Peptide appearance Lyophilized form

Weight Loss

15 000+ verified orders

Cagrilintide

In stock

Cagrilintide is a long-acting analogue of the pancreatic hormone amylin. It is studied as a satiety-signalling peptide, frequently in combination research alongside incretin agonists.
Available strengths
102,50 €
Buy 2, get 1 free. €100 in paid peptide vials · water excluded
Bundle & save

Arrives 26 – 30 November to Europe

We accept Visa Mastercard Apple Pay (when supported) Google Pay (when supported) Klarna (where available) Shown at checkout

Cagrilintide

102,50 €

Long-acting amylin analogue for satiety-signalling and metabolic pathway models.

SKU: ADRIA-CAGRILINTIDE Categories: ,

Compound information

Specifications

Molecular profile

Sequence
{Eicosanedioic acid-gamma-Glu}-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH2 (disulfide Cys3-Cys8)
Molecular mass
4409.0 g/mol
CAS number
1415456-99-3
Molecular formula
C194H312N54O59S2

Material record

Physical appearance
White to off-white lyophilized powder
Solubility
Soluble in bacteriostatic water and suitable aqueous laboratory solvents.
Product note
Amylin analogue research compound; supplied strictly for research use only.

Research overview

Cagrilintide

What is Cagrilintide?

Cagrilintide is a long-acting, lipidated amylin analogue studied in once-weekly clinical regimens. It activates amylin and calcitonin receptors. To understand the broader scientific context for this class, see the complete guide to research peptides.

Originally developed by Novo Nordisk under the research code AM833, cagrilintide received its International Nonproprietary Name (INN) following designation as a clinical candidate. The compound features an amylin-based peptide backbone with sequence modifications and lipidation to support prolonged action.

Key Research Applications

  • Metabolic Research: Cagrilintide’s amylin and calcitonin receptor activity supports studies of satiety and energy intake.
  • Body Composition Studies: Researchers investigating lean mass preservation alongside fat reduction frequently include cagrilintide as a comparator or primary investigational agent in obesity model protocols.
  • Combination Therapy Studies: Phase 1b research compared cagrilintide plus semaglutide with placebo plus semaglutide.

Detailed Mechanism of Action

Cagrilintide acts at amylin receptors and the calcitonin receptor. Structural studies have examined its interactions with AMY1R, AMY2R, AMY3R and CTR, providing a receptor basis for research into amylin-related satiety signalling.

The acylation of cagrilintide extends its plasma half-life dramatically compared to native peptide sequences, enabling once-weekly administration protocols.

Published Research on Cagrilintide

Cagrilintide (AM833) has been the subject of Phase 1 and Phase 2 clinical investigations. Its development as a lipidated, long-acting amylin analogue is described in Development of Cagrilintide, a Long-Acting Amylin Analogue (PMID: 34288673; https://pubmed.ncbi.nlm.nih.gov/34288673/).

Phase 1b clinical research evaluated cagrilintide in combination with semaglutide across multiple escalating dose cohorts. All active cagrilintide groups also received semaglutide; the comparator was placebo plus semaglutide. See the primary trial at https://pubmed.ncbi.nlm.nih.gov/33894838/ (DOI: 10.1016/S0140-6736(21)00845-X).

A separate phase 2 dose-finding trial evaluated once-weekly cagrilintide monotherapy for bodyweight outcomes, safety and tolerability in adults with overweight or obesity. See https://pubmed.ncbi.nlm.nih.gov/34798060/.

The research pipeline around cagrilintide intersects with retatrutide, a GLP-1/GIP/GcgR triple agonist under concurrent development. Researchers should review the retatrutide triple agonist guide and the complete retatrutide guide to understand the structural, potency, and pharmacokinetic differences between these investigational peptides.

Why Choose Cagrilintide?

  • Cagrilintide represents a novel class of long-acting amylin analog peptides, providing a unique pathway for studying satiety, caloric control, and metabolic homeostasis.
  • With its extended half-life, it offers sustained physiological effects and valuable insights into next-generation weight management research.
All presented information is based on scientific publications which can be found in

For laboratory purposes and personal observation only. Not for human consumption.

Laboratory care

Handling

Peptides in transport

Peptides in lyophilized form are supplied in glass vials by standard shipping methods and do not require refrigeration. Short-term temperature fluctuations during transport will not reduce their quality and efficacy. Even at high summer temperatures, the peptides in lyophilized form are stable for several weeks.

Storage of lyophilized peptides

Lyophilized peptides should be stored in a dry place, protected from light and moisture. The following storage conditions are generally recommended:

  • Room temperature (15–25 °C): Up to 3 months
  • Refrigerated (2–8 °C): Up to 6 months
  • Frozen (-20 °C or below): 3–5 years (recommended for long-term storage)

Allow the vial to reach room temperature after taking it out of the refrigerator or freezer.

Storage of reconstituted peptides

Once reconstituted, peptide solutions are generally less stable than their lyophilized form and should be stored under refrigerated conditions whenever possible.

The following storage conditions are generally recommended:

  • Room temperature (15–25 °C): Avoid prolonged storage
  • Refrigerated (2–8 °C): Typically 4–8 weeks
  • Frozen (-20 °C or below): Up to 3–4 months

To preserve peptide integrity, avoid repeated freeze–thaw cycles, as these may accelerate peptide degradation.

Important: Most manufacturers recommend discarding reconstituted peptides within 4 weeks when stored at 2–8 °C. This recommendation is intentionally conservative and may not reflect the actual chemical stability of every peptide. In our own stability studies, many peptides reconstituted in bacteriostatic water showed no detectable degradation after 12 weeks of refrigerated storage. As peptide stability is highly sequence- and formulation-dependent, this result should not be extrapolated to all peptides without supporting stability data.

Analytical documentation

Tests

Latest published result

Liquilabs s.r.o.Signed Certificate of Analysis · 10mg

99.1%Purity by HPLC

Batch number
20265049
Tested
2026-05-28

Recorded QC panel

AssayPeptide screening
10.39 mg
PurityPeptide screening
99.1%
Identity (FTIR)FTIR spectrum
994
Identity (RT)Retention time
0.996

These are the latest published results for this strength. The batch number is printed on each vial. Your supplied batch is confirmed against the matching published record when your order is allocated.

See all test results

Signed certificate

Source record

References

1.

Development of Cagrilintide, a Long-Acting Amylin Analogue PMID: 34288673 DOI: 10.1021/acs.jmedchem.1c00565 https://pubmed.ncbi.nlm.nih.gov/34288673/

2.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial PMID: 33894838 DOI: 10.1016/S0140-6736(21)00845-X https://pubmed.ncbi.nlm.nih.gov/33894838/

3.

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial PMID: 34798060 DOI: 10.1016/S0140-6736(21)01751-7 https://pubmed.ncbi.nlm.nih.gov/34798060/

4.

National Center for Biotechnology Information

PubChem Compound Summary: Cagrilintide

Authoritative identity record for cagrilintide.

PubChem View source ↗
5.

Chemical Abstracts Service

CAS Common Chemistry: 1415456-99-3

Authoritative CAS Registry Number record for cagrilintide.

CAS Common Chemistry View source ↗
6.

Garvey WT, Blüher M, Osorto Contreras CK, et al. · 2025

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity

Primary clinical research report for cagrilintide.

The New England Journal of Medicine · 10.1056/nejmoa2502081 View source ↗
7.

National Center for Biotechnology Information

PubChem compound record

PubChem View source ↗
8.

D'Ascanio AM, Mullally JA, Frishman WH · 2024

Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity

Cardiology in review View source ↗
9.

Carvas AO, Leuthardt A, Kulka P, Lommi G, Hassan S, Coester B, Lundh S, Pers T, Secher A, Raun K, Lutz TA, Le Foll C · 2025

Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3

EBioMedicine View source ↗

Customer reviews

4.7/5185+ reviews
View on Trustpilot ↗Checked 17 Nov 2026

Quality products,fast shipping,great refferal plan,only downside is that products in 4 mounths since my first order got more and more expensive ,but overall verry good experience.

Read full review →

More than 2 weeks for package dispatch. They promised one free peptide next time. Sent me new tracking number but package still wasn't delivered to fedex. Last package (much much cheaper) was delivered in less than week. I will update if they will send my package. ok,package sent.

Read full review →

Extremely satisfied with the product quality and overall experience. The customer service is polite and quick. All recommendations!

Read full review →

Trustworthy site with a huge catalog of products. Been purchasing from them for some time now never got disappointed. I could only recommend them.

Read full review →

Everything ok. With little problem with package, but after contact with Customer Service everything went right. Good quality of products

Read full review →

Excellent. Buying peptides online can be nerve wracking! But Adria are very transparent about all the checks and certifications. My experience with them was excellent. Great products at good prices and efficient P&P

Read full review →